Sanqi ( DrugBank: Sanqi )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 222 | Primary nephrotic syndrome | 1 |
222. Primary nephrotic syndrome
Clinical trials : 310 / Drugs : 295 - (DrugBank : 117) / Drug target genes : 63 - Drug target pathways : 194
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ITMCTR2200006361 | 2022-07-20 | 2022-07-13 | The Efficacy and Safety of Sanqi Qushi Granule in Patients with Idiopathic Membranous Nephropathy --Protocol of a Multicenter, Randomized Control Trial | The Efficacy and Safety of Sanqi Qushi Granule in Patients with Idiopathic Membranous Nephropathy | Idiopathic Membranous Nephropathy (IMN) | Control group:placebo, standard immunosuppressive and basic treatment. ;Sanqi qushi granule Group:Sanqi qushi granule, standard immunosuppressive treatment and basic treatment.; | Guangdong Provincial Hospital of Traditional Chinese Medicine | NULL | Pending | Both | Control group:65;Sanqi qushi granule Group:65; | N/A | China |